Univariable analysis | Multivariable analysis* | |||
---|---|---|---|---|
HR (95% CI) | p | HR (95% CI) | p | |
Clinical factors | ||||
Age† | 1.03 (1.00–1.05) | 0.020 | 1.00 (0.98–1.03) | 0.714 |
Male sex | 0.68 (0.34–1.36) | 0.272 | ||
Symptom duration, days† | 1.00 (0.99–1.01) | 0.450 | ||
Steroid use prior to the treatment | 0.84 (0.39–1.81) | 0.653 | ||
Baseline MELD† | 1.09 (1.04–1.14) | < 0.001 | 1.09 (1.03–1.16) | 0.005 |
Baseline GFR, mL/min/1.73 m2† | 0.99 (0.99–1.00) | 0.064 | 1.00 (1.00–1.01) | 0.623 |
Baseline H-score† | 1.00 (0.99–1.01) | 0.524 | ||
Baseline fibrinogen, mg/dL† | 1.00 (0.99–1.00) | 0.144 | ||
Underlying cause | ||||
Rheumatic disease | 0.93 (0.38–2.25) | 0.864 | ||
Malignancy | 0.49 (0.20–1.20) | 0.119 | ||
Infection | 0.82 (0.35–1.88) | 0.632 | ||
Idiopathic | 2.21 (1.09–4.49) | 0.028 | 2.44 (1.11–5.36) | 0.027 |
Treatment at baseline | ||||
HLH-2004 regimen | 0.69 (0.35–1.39) | 0.302 | ||
Chemotherapy | 0.36 (0.09–1.52) | 0.166 | ||
Other immunosuppressant | 0.54 (0.13–2.26) | 0.400 | ||
Steroid only | 3.21 (1.30–7.95) | 0.012 | 2.85 (0.98–8.30) | 0.056 |
Tocilizumab | 2.92 (1.25–6.82) | 0.013 | 5.55 (2.13–14.49) | < 0.001 |